Jan 11 (Reuters) - Acerus Pharmaceuticals Corporation ASP.TO :
* ACERUS ANNOUNCES REPORTING OF ANTICIPATED SHORTAGE OF ESTRACE®
* ACERUS PHARMACEUTICALS - DOES NOT FORESEE A SHORTFALL OF 2.0 MG DOSE IN NEXT SIX MONTHS BASED ON EXISTING INVENTORY IN STOCK
* ACERUS PHARMACEUTICALS - WAS NOTIFIED THAT MANUFACTURING LICENSE REINSTATEMENT AT FACILITY WHERE ESTRACE IS BEING PRODUCED HAS NOT YET OCCURRED
* ACERUS PHARMACEUTICALS - WORKING WITH MANUFACTURER TO ACCELERATE DELIVERY TIMELINES, UNCLEAR IF SUPPLY TO BE RE-ESTABLISHED IN TIME TO AVOID SHORTAGES
* ACERUS PHARMACEUTICALS CORPORATION - NEXT EXPECTED SHIPMENT OF ESTRACE MAY BE DELAYED
* ACERUS - HAD BEEN NOTIFIED BY ITS CONTRACT MANUFACTURER OF A PARTIAL MANUFACTURING LICENSE SUSPENSION AT FACILITY WHERE ESTRACE IS BEING PRODUCED
* ACERUS - PARTIAL MANUFACTURING LICENSE SUSPENSION AT FACILITY WHERE ESTRACE IS BEING PRODUCED AS A RESULT OF AN AUDIT BY U.K. HEALTH AUTHORITIES
* ACERUS PHARMACEUTICALS CORPORATION - SHOULD SHORTAGES OCCUR OR PERSIST, THIS MAY HAVE AN ONGOING NEGATIVE IMPACT ON ESTRACE REVENUE